Stem cell therapy in refractory perineal Crohn's disease: long‐term follow‐up

Wainstein, C; Quera, Rodrigo; Fluxá, Daniela; Kronberg, Udo; Conejero, Alejandro; López-Köstner, Francisco; Jofré, Claudio; Zárate, Alejandro

doi:10.1111/codi.14002

Cited by 34 publications

(31 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main features found in the 13 included studies are detailed in Figures 2 and 3. Among these, one study is about luminal CD 28 and the other 12 about perianal fistulizing CD 6 , 7 , 11 , 12 , 15 , 16 , 18 , 24 , 25 , 26 , 27 , 30 .…”

Section: Resultsmentioning

confidence: 99%

Transplantation of Adipose-Derived Mesenchymal Stem Cells in Refractory Crohn’s Disease: Systematic Review

Bernardi¹,

Santos

Zorgetto-Pinheiro³

et al. 2019

ABCD, arq. bras. cir. dig.

View full text Add to dashboard Cite

Background:Crohn’s disease is a pathological condition that has different options of treatment, but there are patients who need other therapeutic approach, such as the use of adipose-derived mesenchymal stem cells. Aim:Systematic literature review to determine the different ways of adipose-derived mesenchymal stem cells administration in humans with luminal refractory and perianal fistulizing Crohn’s disease. Methods:It was conducted a search for articles (from 2008 to 2018) on PubMed and ScienceDirect databases using the keywords Crohn’s disease, fistulizing Crohn’s disease, luminal Crohn’s disease and transplantation of mesenchymal stem cells or mesenchymal stem cells or stromal cells. Thirteen publications were selected for analysis. Results:Only one study referred to the luminal Crohn´s disease. The number of cells administered was variable, occurring mainly through subcutaneous adipose tissue by liposuction. It could be highlighted the autologous transplant with exclusive infusion of mesenchymal stem cells. The procedures involved in pre-transplant were mainly curettage, setons placement and stitching with absorbable suture, and conducting tests and drug treatment for luminal Crohn´s disease. During transplant, the injection of mesenchymal stem cells across the fistula path during the transplant was mainly on the intestinal tract wall. Conclusion:Although the use of mesenchymal stem cells is promising, the transplant on the luminal region should be more investigated. The injection of mesenchymal stem cells, exclusively, is more explored when compared to treatment with other products. The preparation of the fistulizing tract and the location of cell transplantation involve standardized health care in most studies.

show abstract

Section: Resultsmentioning

confidence: 99%

Transplantation of Adipose-Derived Mesenchymal Stem Cells in Refractory Crohn’s Disease: Systematic Review

Bernardi¹,

Santos

Zorgetto-Pinheiro³

et al. 2019

ABCD, arq. bras. cir. dig.

View full text Add to dashboard Cite

show abstract

“…Partial healing was defined as external fistula opening remaining but with decrease of > 50% in size. This study found complete healing in 10/11 patients’ fistulas and partial healing in 1/11[ 15 ]. Conclusions were made that excellent success rates can be made for fistulizing CD with a multi-approach treatment method including ASCs, platelet rich plasma, and endorectal advancement flaps.…”

Section: Allogeneic Adipose Tissue Derived Stem Cell Therapy Trialsmentioning

confidence: 97%

“…Wainstein et al[ 15 ] also published a single center prospective observational pilot study conducted between 2013-2016 and included nine patients. Two stages were included in this study which was (1) “examination under anesthesia, fistula mapping, drainage and seton placement” and (2) setons removed four to six weeks with subsequent debridement and ASC then injected with biological plug formation.…”

Section: Allogeneic Adipose Tissue Derived Stem Cell Therapy Trialsmentioning

confidence: 99%

One more chance of fistula healing in inflammatory bowel disease: Stem cell therapy

Turse

Dailey

Naseer

et al. 2018

WJCC

View full text Add to dashboard Cite

Patients with fistulizing inflammatory bowel disease are traditionally difficult to treat. This patient population often experiences delayed or insufficient healing of fistulas using current standard regimens including antibiotics, immunomodulators, anti-tumor necrosis factor-α drug, placement of setons, and surgical repair. Several studies over the last ten to fifteen years have been conducted using stem cell therapies with promising results in this patient population. These studies show stem cell therapy in fistulizing disease to be successful in healing between 60%-88% compared to currently 50% with infliximab. Moreover, remission was seen 24 wk to 52 wk in these studies. Further research with a multi-approach treatment using medications, stem cell therapy, and surgical interventions will likely be the future of this innovative treatment approach.

show abstract

“…Partial healing was defined as external fistula opening remaining but with a decrease of >50% in size. This trial found complete healing in 10/11 patients’ fistulas and 1/11 partial healing 45. The authors decided that excellent success rates can be made for fistulizing CD with a therapy method including alloASC, platelet-rich plasma, and endorectal advancement flaps.…”

Section: Stem Cell Therapy For Fistulizing Diseasementioning

confidence: 99%

“…Finally, Wainstein et al published a single-center prospective observational pilot study conducted during 2013–2016 including nine patients 45. Two stages were included in this trial which were 1) “examination under anesthesia, fistula mapping, drainage and seton placement” and 2) setons removed 4–6 weeks with subsequent debridement and ASC then injected with biological plug formation.…”

Section: Stem Cell Therapy For Fistulizing Diseasementioning

confidence: 99%

Stem cells for luminal, fistulizing, and perianal inflammatory bowel disease: a comprehensive updated review of the literature

Turse

Dailey

Naseer

et al. 2018

SCCAA

View full text Add to dashboard Cite

Much research has been performed over the last decade on stem cell therapy as treatment for patients with inflammatory bowel disease. Hematopoietic and mesenchymal stem cells, both allogeneic (from someone else) and autologous (from own patient), have been studied with safe and efficacious results in the majority of patients treated for luminal, perianal, and/or fistulizing disease. Here in this review, we highlight all human trials that have been conducted utilizing stem cell therapy treatment in patients with inflammatory bowel disease.

show abstract

Stem cell therapy in refractory perineal Crohn's disease: long‐term follow‐up

Abstract: Combined therapy with adipose-mesenchymal stem cells, platelet-rich plasma and endorectal advancement flaps yielded good results in patients with refractory Perineal Crohn's Disease. This article is protected by copyright. All rights reserved.

Cited by 34 publications

References 39 publications

Transplantation of Adipose-Derived Mesenchymal Stem Cells in Refractory Crohn’s Disease: Systematic Review

Transplantation of Adipose-Derived Mesenchymal Stem Cells in Refractory Crohn’s Disease: Systematic Review

One more chance of fistula healing in inflammatory bowel disease: Stem cell therapy

Stem cells for luminal, fistulizing, and perianal inflammatory bowel disease: a comprehensive updated review of the literature

Contact Info

Product

Resources

About